Figure 1 (Xeomin 01)
Xeomin Injection, Powder, Lyophilized, For Solution
Product Images NDC 0259-4150
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Xeomin (NDC 0259-4150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Merz Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Xeomin 01a
Figure 2 (Xeomin 02)
The text describes a list of muscles in the upper limb of the body, including the biceps brachii, brachioradialis, brachialis, pronator teres, flexor digitorum profundus, flexor carpi radialis, flexor pollicis longus, flexor digitorum superficialis, flexor carpi ulnaris, pronator quadratus, opponens pollicis, flexor pollicis brevis, and adductor pollicis.*
Figure 3 (Xeomin 03)
This text seems to be describing the muscles and tendons in the anterior upper limb. It includes names such as pronator quadratus, flexor pollicis longus, and adductor pollicis, as well as mention of the muscles' tendons. However, there are some words that are unreadable, making it challenging to provide a complete and accurate description.*
Xeomin 03a
Figure 4 (Xeomin 04)
This text provides information about the muscles surrounding the eye, specifically the orbicularis oculi and the corrugator muscle. It identifies different parts of the orbicularis oculi muscle and their location around the eye. The text is relevant for anyone interested in anatomy, physiology or medicine related to the muscles of the eye.*
Figure 5 (Xeomin 05)
The text refers to the names of two muscles: the Occipitofrontalis and the Corrugator. No further information is available.*
Figure 6 (Xeomin 06)
This appears to be a table that shows the percentage of patients who experienced different levels of change in their GICS score (a measure of active treatment efficacy) when treated with Xeomin or a placebo. The table includes columns indicating the degree of change in symptom severity and rows indicating the percentage of patients who experienced each level of change, ranging from "very much worse" to "very much improved".*
Principal Display Panel (50 Units/Vial Label)
Principal Display Panel (50 Units/Vial Carton)
Principal Display Panel (100 Units/Vial Label)
Principal Display Panel (100 Units/Vial Carton)
Principal Display Panel (50 Units/Vial Label)
This is a description of a medication named "incobotulinumtoxinA" which is also sold under the brand name "Xeomin". Each vial of this injection contains 50 units and is indicated for intramuscular and intraglandular use. The product should be stored in a refrigerator at 2 to 8°C (36 to 46°F) and should not be stored above 25°C (77°F). It is manufactured by Merz Pharmaceuticals GmbH and distributed by Merz Pharmaceuticals, LLC. The dosage should be determined as per the package directions. The text also contains warnings stating that dosing units of botulinum toxins between different commercial products are not interchangeable.*
Principal Display Panel (50 Units/Vial Carton)
This is a description of a drug called "incobotulinumtoxinA" which is also known as "xeomin". It is injected into muscles or glands, and comes in a single-dose vial with a strength of 100 units. The drug should only be used according to the instructions provided in the package insert and any unused portions should be discarded. It is important to note that dosing units of botulinum toxin products are not interchangeable between products. The drug is manufactured by Merz Pharmaceuticals GmbH and distributed by Merz Pharmaceuticals, LLC. The text also includes several identification numbers and warnings to healthcare professionals.*
Principal Display Panel (100 Units/Vial Label)
incobotulinumtoxinA is a medication that comes in a 50 units/vial presentation. Each vial contains 50 uris of Single-dose vial, and the usual dosage can be found in the package. The medication should be stored in a refrigerator at 2 to 8°C (36 to 46°F), and it is not for resale. This is a physician's sample. The product should not be used for intraglandular use, and it should not be stored above 25°C (77°). The medication is distributed by Mez Pharmaceuticals LLC, and it comes with a guide to each patient.*
Principal Display Panel (100 Units/Vial Carton)
XEOMIN is a medication used for Intramuscular and Intraglandular Use, which contains the toxin produced by the bacterium Clostridium Botulinum. It is available in single-use vials that contain 100 units of the neurotoxin. The dosage regimen is indicated on the package, and it should be administered by a physician only. The potency in U.S. Standard is not specified, and it is essential to be aware that dosing units of botulinum toxins are not interchangeable between commercial products. The medication is manufactured by Merz Pharmaceuticals, LLC, and it should be used for up to 24 hours after mixing with 0.9% Sodium Chloride Injection.*
Principal Display Panel (200 Units/Vial Label)
This is a product description of a medication called incobotulinumtoxinA, also known as Xeomin®. The medication is for injection and comes in a vial containing 200 units of Clostridium Botulinum Neurotoxin. It is for intramuscular and intraglandular use but there is a warning that dosing units of botulinum toxins are not interchangeable between commercial products. The medication is distributed by Merz Pharmaceuticals, LLC and comes with a guide to be dispensed to each patient. The text also includes some technical information such as the product's ArtNr, AW numbers, MN, and MC numbers.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
